Hospital Clínico San Carlos

Running trials

• Not yet recruiting

  Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors

  NCT06139783· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Source

• Not yet recruiting

  Rimonabant for Improving Walking Ability in Patients With Chronic Stroke

  NCT07913763· Phase 2· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Source

• Recruiting

  Evaluation of the Safety and Efficacy of Rimonabant on Cognitive impairment in patients with post-COVID-19 Syndrome.

  2023-507870-42-00· Phase 2· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Source

• Not yet recruiting

  Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes

  NCT07401901· Source

• Recruiting

  A Study of DS-3939a in Participants With Solid Tumors

  NCT07739966· Phase 1/2· Source

• Recruiting

  A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.

  2025-525030-57-00· Phase 3· Source

• Not yet recruiting

  A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

  2026-526184-38-00· Phase 2· Source

• Not yet recruiting

  Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

  NCT07247786· Phase 2· Source

• Not yet recruiting

  Prevention of Infection of the Respiratory Tract Through Application of Non-Invasive Methods of Secretion Suctioning

  NCT06113939· Phase 4· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Source

• Not yet recruiting

  Effects of a CB1 Antagonist/Inverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.

  2025-521689-86-00· Phase 2· Source

• Recruiting

  A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  NCT07807163· Phase 2· Source

• Not yet recruiting

  Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

  NCT07717099· Phase 2· Source

• Not yet recruiting

  Multicentre, randomized, open label study comparing the concomitant administration of trabectedin and low-dose radiotherapy versus trabectedin alone in patients with advanced sarcoma

  2026-525703-27-00· Phase 4· Source

• Recruiting

  A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

  NCT07460986· Phase 1/2· Source

• Recruiting

  A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.

  2025-524488-18-00· Phase 2· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Source

• Recruiting

  A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

  NCT07636811· Phase 2· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

  2025-524336-19-00· Phase 3· Source

• Recruiting

  BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

  NCT07625644· Phase 3· Source

• Recruiting

  BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer

  NCT07492641· Phase 3· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Source

• Recruiting

  Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

  NCT07478991· Phase 3· Source

• Recruiting

  Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

  NCT07476287· Phase 2· Source

• Recruiting

  BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])

  NCT07666490· Phase 4· Source

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Source

• Recruiting

  A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  NCT07365319· Phase 2/3· Source

• Recruiting

  Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

  NCT07333066· Phase 3· Source

• Recruiting

  Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material

  NCT07403825· Phase 4· Source

• Recruiting

  Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients

  NCT07242547· Phase 2· Source

• Recruiting

  Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

  NCT07566156· Phase 3· Source

• Recruiting

  Prospective randomized study on sexual health and self-perceived quality of life (PROMs) in patients treated for cervical cancer

  2025-521460-36-00· Phase 4· Source

• Recruiting

  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  NCT07513376· Phase 3· Source

• Not yet recruiting

  REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices

  NCT07611188· Source

• Not yet recruiting

  Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.

  2025-524363-20-01· Phase 2· Source

• Recruiting

  A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy

  2025-522979-29-00· Phase 3· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Source

• Active, not recruiting

  AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

  NCT07503210· Phase 3· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Source

• Recruiting

  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  NCT07431827· Phase 3· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Source

• Not yet recruiting

  Treatment for Ph-negative ALL for Adults up to 65 Years

  NCT07443592· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer44 recruiting
• Prostate cancer18 recruiting
• Metastatic breast cancer17 recruiting
• Bladder cancer14 recruiting
• Ovarian cancer11 recruiting
• Alzheimer disease10 recruiting
• Colorectal cancer9 recruiting
• Head and neck cancer9 recruiting
• Gastric and esophageal cancer8 recruiting
• Stroke8 recruiting
• Heart failure7 recruiting
• Childhood cancers6 recruiting
• Coronary artery disease6 recruiting
• Endometrial cancer6 recruiting
• Pancreatic cancer6 recruiting
• Sarcoma6 recruiting
• Kidney cancer5 recruiting
• Melanoma5 recruiting
• Multiple sclerosis5 recruiting
• Atrial fibrillation4 recruiting
• Cervical cancer4 recruiting
• Migraine4 recruiting
• Obesity4 recruiting
• Epilepsy3 recruiting
• Schizophrenia3 recruiting
• Acute myeloid leukemia2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Endometriosis2 recruiting
• HIV2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lupus (SLE)2 recruiting
• Multiple myeloma2 recruiting
• Rheumatoid arthritis2 recruiting
• Thyroid cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Chronic kidney disease1 recruiting
• Follicular lymphoma1 recruiting
• Frontotemporal dementia1 recruiting
• Glaucoma1 recruiting
• Glioblastoma1 recruiting
• Long COVID and ME/CFS1 recruiting
• Macular degeneration1 recruiting
• Mesothelioma1 recruiting
• Myasthenia gravis1 recruiting
• Osteoporosis1 recruiting
• Parkinson disease1 recruiting
• Sickle cell disease1 recruiting
• Sjögren's disease1 recruiting
• Thalassaemia1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Evaluation of the Risk of Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

  NCT07719621· Source

• Completed

  NutriTrack: AI-Assisted Nutritional Tracking in the Obesity Clinic

  NCT07588620· Source

• Completed

  A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures

  2025-524038-24-00· Phase 3· Source

• Completed

  Clinical trial in multiple hospitals to explore new ways to diagnose and monitor tuberculosis treatment

  2025-522235-34-00· Phase 4· Source

• Completed

  A Study Evaluating BFB759 in Atopic Dermatitis

  2025-521624-30-00· Phase 2· Source

• Completed

  Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in post-COVID-19 POTS

  NCT06524739· Phase 3· Source

• Completed

  A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with post COVID-19 syndrome

  2024-517199-39-00· Phase 2· Source

• Completed

  Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

  2024-512505-66-00· Phase 2/3· Source

• Active, not recruiting

  Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

  NCT06806293· Phase 3· Source

• Completed

  N/A

  2024-513121-22-00· Phase 2· Source

• Completed

  Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

  NCT05828303· Phase 1· Source

• Completed

  A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer

  2024-514048-98-00· Phase 3· Source

• Completed

  A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)

  NCT06723288· Source

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  NCT06717698· Phase 2· Source

• Completed

  A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)

  2024-514559-13-00· Phase 2/3· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant

  2024-511557-21-00· Phase 3· Source

• Active, not recruiting

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· Phase 2· Source

• Completed

  A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus

  NCT06413511· Phase 1· Source

• Completed

  A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic lung cancer

  2023-506882-70-00· Phase 3· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Source

• Active, not recruiting

  A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

  NCT06483334· Phase 1/2· Source

• Completed

  A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib

  NCT06200714· Source

• Completed

  A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced lung cancer.

  NCT06173505· Phase 1/2· Source

• Completed

  A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis

  2023-508992-35-00· Phase 2· Source

• Completed

  A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

  NCT06395753· Phase 2· Source

• Completed

  A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

  NCT06188559· Phase 2· Source

• Completed

  A proof of concept and dose-finding study of XXB750 in patients with heart failure

  2023-504678-39-00· Phase 2· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Source

• Completed

  A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

  NCT06168409· Phase 3· Source

• Completed

  THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+)

  2023-507304-32-00· Phase 4· Source

• Completed

  VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

  NCT06214052· Phase 2· Source

• Completed

  Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

  NCT05962606· Phase 2· Source

• Completed

  Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.

  2022-502413-29-00· Phase 2· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Source

• Completed

  A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma.

  NCT04718675· Phase 1· Source

• Completed

  Oral Nutritional Supplement in Type 2 Diabetes Subjects With or at Risk of Malnutrition

  NCT05913193· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· Phase 3· Source

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Source

• Completed

  A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis

  NCT06073119· Phase 2· Source

• Completed

  Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

  NCT06039579· Phase 2· Source

• Completed

  Development of a Molecular Diagnostic Tool for Endometrial Cancer.

  NCT06192017· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

  2022-502828-42-00· Phase 2· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

  NCT05909904· Phase 2· Source

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Source

• Completed

  Characteristics of Sexual Dysfunction in Patients With Lung Cancer

  NCT06018376· Source

• Active, not recruiting

  Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

  NCT05644561· Phase 3· Source

• Active, not recruiting

  A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

  NCT05845814· Phase 1/2· Source